AHMEDABAD, India and PARIS, April 17, 2025 /PRNewswire/ — Following the announcement of its envisaged tender offer on March 11, 2025, Zydus Lifesciences Limited announces the execution of undertakings from 7 shareholders to tender 2,236,911 Amplitude Surgical shares, representing 4.7% of the company’s capital and voting rights by them.
Considering the 85.6% of the capital that will be acquired by Zydus Lifesciences Limited from PAI Partners, the management of Amplitude Surgical and two minority shareholders, Zydus Lifesciences Limited will be in a position with these undertakings to acquire more than 90% of the capital and voting rights of Amplitude Surgical at the end of the tender offer.
These undertakings to tender 2,236,911 Amplitude Surgical shares, representing 4.7% of the company’s capital and voting rights, may be revoked in the event of a competing tender offer being filed by a third party, declared compliant and opened by the Autorité des marchés financiers.
The acquisition of the 85.6% block is expected to be completed by June 2025 and the draft tender offer will be filed with the Autorité des marchés financiers upon receipt of regulatory approvals. The opening of the tender offer will then be subject to the clearance decision of the Autorité des marchés financiers.
Logo: https://mma.prnewswire.com/media/2592545/Zydus_Lifesciences_Limited_Logo.jpg